比利时放疗可及性:我们离循证利用率还有多远?
该研究对比利时2009-2010年110,810例独特癌症诊断的实际放疗利用率与ESTRO-HERO项目的最优利用率及多学科团队建议放疗进行比较。总体实际利用率为37%(含近距离放疗为39%),低于最优利用率53%,但与建议放疗(35%)一致。结论认为实际放疗与多学科团队建议吻合良好,但低于循证最优水平,需进一步分析潜在障碍。
要点
- 总体实际放疗利用率为37%(含近距离放疗39%),低于最优利用率53%,与建议放疗35%一致。
- 不同肿瘤类型差异大,肺癌和前列腺癌实际利用率远低于最优利用率,乳腺癌和直肠癌一致性较好。
- 84%的治疗在诊断后9个月内开始;生存时间以肿瘤类型依赖的方式影响实际利用率;老年患者接受放疗较少。
核心结论
- 比利时实际放疗利用率与多学科团队建议吻合良好,但低于循证最优水平。
- 需进一步分析潜在障碍,以用于放疗预测和规划并促进放疗的适当可及性。
研究设计与样本
- 对比利时2009-2010年110,810例独特癌症诊断的回顾性分析,比较实际利用率、最优利用率及多学科团队建议放疗。
- 实际利用率来自报销数据,区分姑息与根治性外照射放疗和/或近距离放疗;建议放疗基于多学科团队会议报告的宽泛治疗类别计算。
- 进行了关于随访期、生存长度和患者年龄影响的敏感性分析。
主要发现
- 总体实际利用率为37%(含近距离放疗为39%),低于最优利用率53%,但与建议放疗35%一致。
- 肿瘤类型间差异大:肺癌和前列腺癌实际利用率远低于最优利用率,乳腺癌和直肠癌一致性较好。
- 总体84%的治疗在诊断后9个月内开始;生存时间以肿瘤类型依赖的方式影响实际利用率;老年患者接受放疗较少。
关键数值与推荐
- 最优利用率采用ESTRO-HERO项目(欧洲放射肿瘤学会-放射肿瘤学健康经济学)的比例。
- 实际利用率总体37%(含近距离放疗39%),建议放疗35%,最优利用率53%。
临床怎么用
- 原文未据此给出推荐。
局限性
- 原文未报告局限性。
以上解读依据论文摘要(全文未开放获取或许可不允许翻译转载)。
原文
INTRODUCTION: Underutilisation of radiotherapy has been observed worldwide. To evaluate the current situation in Belgium, optimal utilisation proportions (OUPs) adopted from the European SocieTy for Radiotherapy and Oncology - Health Economics in Radiation Oncology (ESTRO-HERO) project were compared to actual utilisation proportions (AUPs) and with radiotherapy advised during the multidisciplinary cancer team (MDT) meetings. In addition, the impact of independent variables was analysed. MATERIALS AND METHODS: AUPs and advised radiotherapy were calculated overall and by cancer type for 110,810 unique cancer diagnoses in 2009-2010. Radiotherapy utilisation was derived from reimbursement data and distinguished between palliative and curative intent external beam radiotherapy (EBRT) and/or brachytherapy (BT). Sensitivity analyses regarding the influence of the follow-up period, the survival length and patient's age were performed. Advised radiotherapy was calculated based on broad treatment categories as reported at MDT meetings. RESULTS: The overall AUP of 37% (39% including BT) was lower than the OUP of 53%, but in line with advised radiotherapy (35%). Large variations by tumour type were observed: in some tumours (e.g. lung and prostate cancer) AUP was considerably lower than OUP, whereas in others there was reasonable concordance (e.g. breast and rectal cancer). Overall, 84% of treatments started within 9 months following diagnosis. Survival time influenced AUP in a cancer type-dependent way. Elderly patients received less radiotherapy. CONCLUSION: Although the actually delivered radiotherapy in Belgium aligns well to MDT advices, it is lower than the evidence-based optimum. Further analysis of potential barriers is needed for radiotherapy forecasting and planning, and in order to promote adequate access to radiotherapy.
引用
- Lievens Y, De Schutter H, Stellamans K, et al. Radiotherapy access in Belgium: How far are we from evidence-based utilisation? Eur J Cancer. 2017. PMID: 28802187. doi:10.1016/j.ejca.2017.07.011
供执业医师工作参考,不替代临床判断;数值与分级以指南原文为准。